Results 11 to 20 of about 39,428 (277)

Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Journal for ImmunoTherapy of Cancer, 2019
Background Angiosarcoma is an uncommon endothelial malignancy and a highly aggressive soft tissue sarcoma. Due to its infiltrative nature, successful management of localized angiosarcoma is often challenging.
Vaia Florou, Andrew E. Rosenberg, Eric Wieder, Krishna V. Komanduri, Despina Kolonias, Mohamed Uduman, John C. Castle, Jennifer S. Buell, Jonathan C. Trent, Breelyn A. Wilky   +9 more
doaj   +2 more sources

Recurring radiation-induced angiosarcoma of the breast that was treated with paclitaxel chemotherapy: a case report

Surgical Case Reports, 2020
Background Angiosarcoma of the breast is very rare and can be divided into primary and secondary angiosarcoma. Radiation-induced angiosarcoma (RIAS) is classified as secondary angiosarcoma.
Yoko Suzuki, Kohei Taniguchi, Minami Hatono, Yukiko Kajiwara, Yuko Abe, Kengo Kawada, Takahiro Tsukioki, Mariko Kochi, Keiko Nishiyama, Takayuki Iwamoto, Hirokuni Ikeda, Tadahiko Shien, Naruto Taira, Masahiro Tabata, Hiroyuki Yanai, Hiroyoshi Doihara   +15 more
doaj   +2 more sources

Diffused hepatic angiosarcoma with Kasabach-Merritt syndrome-case report and literature review

BMC Gastroenterology, 2020
Background Hepatic angiosarcoma is a rare malignant tumor featured by highly aggressive behavior and poor prognosis. There are few reports about diffused hepatic angiosarcoma with Kasabach-Merritt syndrome till now.
Xing-mao Zhang, Yao Tong, Qing Li, Qiang He   +3 more
doaj   +2 more sources

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for ImmunoTherapy of Cancer, 2021
Purpose Angiosarcoma is a rare aggressive endothelial cell cancer with high mortality. Isolated reports suggest immune checkpoint inhibition efficacy in angiosarcoma, but no prospective studies have been published.
M. Wagner, M. Othus, S. Patel, C. Ryan, A. Sangal, Benjamin Powers, G. Budd, A. Victor, C. Hsueh, R. Chugh, S. Nair, K. Leu, M. Agulnik, E. Sharon, E. Mayerson, M. Plets, C. Blanke, H. Streicher, Y. Chae, R. Kurzrock   +19 more
semanticscholar   +1 more source

Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center

Journal for ImmunoTherapy of Cancer, 2022
Background Angiosarcoma is a histologically and molecularly heterogeneous vascular neoplasm with aggressive clinical behavior. Emerging data suggests that immune checkpoint blockade (ICB) is efficacious against some angiosarcomas, particularly cutaneous ...
E. Rosenbaum, C. Antonescu, Shaleigh A. Smith, M. Bradic, Daniel Kashani, A. Richards, M. Donoghue, C. Kelly, B. Nacev, J. Chan, Ping Chi, M. Dickson, M. Keohan, M. Gounder, S. Movva, V. Avutu, K. Thornton, A. Zehir, A. Bowman, S. Singer, W. Tap, S. D’Angelo   +21 more
semanticscholar   +1 more source

Scalp angiosarcoma treated with linear accelerator-based boron neutron capture therapy: A report of two patients

Clinical and Translational Radiation Oncology, 2022
Highlights • Scalp-angiosarcoma is difficult to manage, and surgery is the primary therapy.• BNCT can deliver highly effective particles more selectively to tumor cells.• BNCT requires a high neutron flux that typically can only be supplied by a nuclear ...
H. Igaki, N. Murakami, Satoshi Nakamura, N. Yamazaki, T. Kashihara, A. Takahashi, K. Namikawa, M. Takemori, Hiroyuki Okamoto, K. Iijima, Takahito Chiba, Hiroki Nakayama, A. Takahashi, T. Kaneda, Kana Takahashi, K. Inaba, K. Okuma, Y. Nakayama, K. Shimada, H. Nakagama, J. Itami   +20 more
semanticscholar   +1 more source

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma

JAMA Oncology, 2022
This randomized clinical trial investigates whether carotuximab plus pazopanib improves progression-free survival vs pazopanib alone in adult patients with advanced angiosarcoma.
Robin L. Jones, V. Ravi, A. Brohl, S. Chawla, K. Ganjoo, A. Italiano, S. Attia, M. Burgess, K. Thornton, L. Cranmer, M. Cheang, Lingyun Liu, L. Robertson, B. Adams, C. Theuer, R. Maki   +15 more
semanticscholar   +1 more source

Primary Angiosarcoma of the Breast: A Single-Center Retrospective Study in Korea

Current Oncology, 2022
Due to the rarity of primary angiosarcoma of the breast, optimal management is based on expert opinion. The aim of this study was to review all primary angiosarcomas of the breast obtained from a single center in terms of clinicopathologic ...
Yeon-Jin Kim, J. Ryu, Sekyung Lee, B. Chae, S. Kim, S. Nam, Jonghan Yu, Jeong-Eon Lee   +7 more
semanticscholar   +1 more source

Primary splenic angiosarcoma: case report and literature review

Revista Brasileira de Cancerologia, 2022
This paper describes a case of an aggressive primary splenic angiosarcoma in a 29-year-old man and makes a review of its clinicai findings, pathologic reports, treatment and prognosis. Angiosarcomas comprise less than 1% of soft tissue sarcomas, and only
L. Venegas, P. Pohlmann, A. Balbinot, Eduardo Schuck, Carla T. M. de Oliveira, K. Frank, Carlos F. Dillemburg, Mário S. B. da Costa, L. Rivero, A. C. Pütten   +9 more
semanticscholar   +1 more source

OER‐073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma

Cancer, 2022
Angiosarcomas are rare mesenchymal sarcomas that can present as primary cutaneous or noncutaneous disease. They express a variety of vascular endothelial growth factor receptors. The authors hypothesized that the treatment of angiosarcoma with pazopanib,
Julio Alvarenga Thiebaud, V. Ravi, S. Litwin, S. Schuetze, S. Movva, M. Agulnik, A. Kraft, E. Tetzlaff, N. Somaiah, M. von Mehren   +9 more
semanticscholar   +1 more source